Bolt Biotherapeutics Stock Performance
| BOLT Stock | USD 0.60 0.02 3.45% |
The firm shows a Beta (market volatility) of 0.0825, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Bolt Biotherapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Bolt Biotherapeutics is expected to be smaller as well. At this point, Bolt Biotherapeutics has a negative expected return of -0.19%. Please make sure to confirm Bolt Biotherapeutics' value at risk, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Bolt Biotherapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Bolt Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's essential indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors. ...more
1 | The Schall Law Firm Invites Investors To Contribute To A Securities Fraud Lawsuit Against Bolt Biotherapeutics Inc | 09/05/2024 |
2 | Bolt Biotherapeutics, Inc. Short Interest Update | 09/18/2024 |
3 | Daily Americas Richest Family Has Its First Centibillionaire | 09/26/2024 |
4 | Bolt Biotherapeutics Stock Surges Amid Biotech Sector Volatility | 10/07/2024 |
5 | Acquisition by Ocallaghan Brian of 25000 shares of Bolt Biotherapeutics subject to Rule 16b-3 | 10/11/2024 |
6 | Acquisition by Healy James of 25000 shares of Bolt Biotherapeutics subject to Rule 16b-3 | 10/14/2024 |
7 | Acquisition by William Quinn of 250000 shares of Bolt Biotherapeutics at 1.59 subject to Rule 16b-3 | 10/18/2024 |
8 | Arcturus Therapeutics Reports Q3 Loss, Lags Revenue Estimates | 11/07/2024 |
9 | Bolt Biotherapeutics Third Quarter 2024 Earnings Misses Expectations - Yahoo Finance | 11/15/2024 |
10 | Disposition of 44000 shares by Sarah Nemec of Bolt Biotherapeutics at 3.08 subject to Rule 16b-3 | 11/20/2024 |
| Begin Period Cash Flow | 10.8 M |
Bolt |
Bolt Biotherapeutics Relative Risk vs. Return Landscape
If you would invest 69.00 in Bolt Biotherapeutics on August 28, 2024 and sell it today you would lose (9.00) from holding Bolt Biotherapeutics or give up 13.04% of portfolio value over 90 days. Bolt Biotherapeutics is currently does not generate positive expected returns and assumes 2.5135% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Bolt, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bolt Biotherapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bolt Biotherapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bolt Biotherapeutics, and traders can use it to determine the average amount a Bolt Biotherapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0758
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BOLT |
Estimated Market Risk
| 2.51 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.19 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Bolt Biotherapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bolt Biotherapeutics by adding Bolt Biotherapeutics to a well-diversified portfolio.
Bolt Biotherapeutics Fundamentals Growth
Bolt Stock prices reflect investors' perceptions of the future prospects and financial health of Bolt Biotherapeutics, and Bolt Biotherapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bolt Stock performance.
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (14.93) % | ||||
| Current Valuation | (13.48 M) | ||||
| Shares Outstanding | 38.27 M | ||||
| Price To Earning | 36.55 X | ||||
| Price To Book | 0.31 X | ||||
| Price To Sales | 1.98 X | ||||
| Revenue | 7.88 M | ||||
| Gross Profit | 1.62 M | ||||
| EBITDA | (74.34 M) | ||||
| Net Income | (69.2 M) | ||||
| Cash And Equivalents | 176.34 M | ||||
| Cash Per Share | 4.68 X | ||||
| Total Debt | 20.22 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 9.73 X | ||||
| Book Value Per Share | 2.96 X | ||||
| Cash Flow From Operations | (69.53 M) | ||||
| Earnings Per Share | (1.71) X | ||||
| Market Capitalization | 22.14 M | ||||
| Total Asset | 159.78 M | ||||
| Retained Earnings | (364.29 M) | ||||
| Working Capital | 85.25 M | ||||
| Current Asset | 53.49 M | ||||
| Current Liabilities | 9.12 M | ||||
About Bolt Biotherapeutics Performance
Assessing Bolt Biotherapeutics' fundamental ratios provides investors with valuable insights into Bolt Biotherapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Bolt Biotherapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (68.66) | (65.22) | |
| Return On Tangible Assets | (0.43) | (0.45) | |
| Return On Capital Employed | (0.55) | (0.57) | |
| Return On Assets | (0.43) | (0.45) | |
| Return On Equity | (0.61) | (0.58) |
Things to note about Bolt Biotherapeutics performance evaluation
Checking the ongoing alerts about Bolt Biotherapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bolt Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bolt Biotherapeutics generated a negative expected return over the last 90 days | |
| Bolt Biotherapeutics has some characteristics of a very speculative penny stock | |
| Bolt Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 7.88 M. Net Loss for the year was (69.2 M) with profit before overhead, payroll, taxes, and interest of 1.62 M. | |
| Bolt Biotherapeutics currently holds about 176.34 M in cash with (69.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Bolt Biotherapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 58.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 44000 shares by Sarah Nemec of Bolt Biotherapeutics at 3.08 subject to Rule 16b-3 |
- Analyzing Bolt Biotherapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bolt Biotherapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Bolt Biotherapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bolt Biotherapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bolt Biotherapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bolt Biotherapeutics' stock. These opinions can provide insight into Bolt Biotherapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Bolt Stock Analysis
When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.